Some of functionality may not work while you disabled JavaScript. Enable JavaScript for better User Exprience.
Access here alternative investment news about Biohaven Showcases Positive Data On Rimegepant, Oral Cgrp Receptor Antagonist, With 16 Presentations At 2019 American Headache Society (ahs) Annual Scientific Meeting Demonstrating Efficacy In Multiple Patient Types And Long-term Safety
LPNEWS

Biohaven Showcases Positive Data On Rimegepant, Oral Cgrp Receptor Antagonist, With 16 Presentations At 2019 American Headache Society (ahs) Annual Scientific Meeting Demonstrating Efficacy In Multiple Patient Types And Long-term Safety

by prnewswire.com posted 1week ago 174 views
NEW HAVEN, Conn., July 11, 2019 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), today announced it will present 16 scientific presentations (oral and poster) highlighting new efficacy and safety data for rimegepant from Biohaven's robust clinical development...

In this article